Skip to Content
  • Kratom and the FDA

    The FDA has made an announcement about kratom, a plant preparation (Mitragyna speciosa) that (depending on who you ask) is a drug of abuse or a way for people… Read More
  • A New Look at Clinical Success Rates

    Andrew Lo of MIT and his co-workers have published a really interesting paper on clinical trial probability-of-success numbers. It appears to be the largest suc… Read More
  • Hospitals Making Drugs?

    This story from the New York Times got a lot of attention yesterday, and understandably so. It’s fundamentally about the shortage of some generic drugs, a… Read More
  • When Small Trials Convince

    This is a good piece by Bruce Booth in Forbes, and it points out something that’s changing in the biopharma landscape. Readers will have noticed over the… Read More
  • Mongersen Fails

    Readers may recall a post here last year about an odd trial of an antisense drug for Crohn’s disease. Celgene had acquired the drug (mongersen, GED-301)… Read More
  • A Painful, Unacceptable Lack of Data

    Okay, this paper is not going to make a lot of people happy. The authors are reviewing oncology approvals by the European Medicines Agency (EMA) from 2009 to 20… Read More
Page 1 of 2412345...1020...Last »